Former Insys CEO Agrees to Plead Guilty in Fentanyl Scheme

Just weeks before his trial was set to begin, the former chief executive of Insys Therapeutics Inc. has agreed to plead guilty to his role in a scheme to bribe doctors to prescribe a powerful opioid, U.S. prosecutors said on Wednesday. Reuters reports that Michael Babich, 42, has agreed to plead guilty to conspiracy and mail fraud charges, federal prosecutors in Boston said in a court filing. Terms of the plea deal were not disclosed. Babich resigned as Insys Therapeutics’ CEO in 2015. Prosecutors allege that from 2012 to 2015, Babich and others conspired to bribe doctors to prescr...